Abstract: The invention relates to an endothelin antagonistic peptide of the formula (I): X-A-Trp-B-Gly-Thr-E-G-Y   (I) SEQ ID NO: 2 wherein represents Asn or Asp; B represents His or Lys; E represents Ala or Ser; G represents Ala or Pro; X represents X1-Gly or  and Y represents hydroxy, lower alkoxy, amino, wherein X1, X3, Y1, Y2 and Z are further defined, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to recombinant DNA comprising DNA coding for smooth-muscle-type myosin heavy chain SM1 isoform protein inserted into vector DNA, a microorganism carrying the recombinant DNA, and an agent for treatment of arteriosclerosis comprising the recombinant DNA. The recombinant DNA of the present invention can be used effectively as an agent for gene therapy of restenosis after PTCA treatment.

Abstract: Disclosed in a peptide represented by the following formula (I):

Abstract: A medicament for the therapeutic treatment of diabetes which comprises as an active ingredient a compound represented by the general formula (I): wherein R1 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, R2 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, R3 represents a hydrogen atom, a lower alkyl group or a substituted or unsubstituted aralkyl group, X1 and X2 independently represent a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group, and the symbol “n” represents an integer of from 0 to 3, or a physiologically acceptable salt thereof.

Abstract: The invention relates to biologically pure cultures of Streptomyces sp. RE-701 (FERM BP-3624) and Streptomyces sp. RE-629 (FERM BP-4126) that produce endothelin antagonistic peptides.

Abstract: The present invention relates to a novel compound EI-2128-1 having IL-1 production inhibitory activity which is represented by formula (I): ##STR1##

Abstract: Provided is an Interleukin-1 production inhibiting compound represented by formula (I) ##STR1## wherein R denotes 4-methyl-1-pentenyl, 5-methyl-1,3-heptadienyl or 1-methylpentanyl.

Abstract: The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.

Abstract: The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.

Abstract: The present invention relates to EI-1941 compounds having interleukin-1 production inhibitory activity which are represented by the formula: ##STR1## wherein either of R.sup.1 and R.sup.2 is hydrogen and the other is hydroxy, or R.sup.1 and R.sup.2 together represent oxygen; and R.sup.3 is hydroxy and R.sup.4 is hydrogen, or R.sup.3 and R.sup.4 together represent --0--.

Abstract: Peptides represented by the following formula (I): ##STR1## wherein A represents Asn or Asp; B represents His or Lys; and E represents Ala or Ser;(1) X.sup.1 and Y.sup.1 are combined together to form a single bond as X.sup.1 --Y1, or (2) X.sup.1 represents hydrogen and Y.sup.1 represents hydroxy;and Z represents, in case of (1),Trp-Phe-Phe-Asn-Tyr-Tyr-7Hyt-Z.sup.1Trp-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp-Z.sup.1,Trp-Val-Tyr-Tyr-Ala-His-Leu-Asp-Ile-Ile-Trp-Z.sup.1,Trp-Leu-Tyr-Phe-Ala-His-Gln-Asp-Val-Ile-Trp-Z.sup.1,Trp-Phe-Phe-Asn-Tyr-R-T-Z.sup.1wherein Z.sup.1 is an organic moiety,wherein R is Tyr or a covalent bond,T is Trp, Ala, Phe, Tyr, Trp-Trp, Asn-Tyr-Tyr-Trp, Trp-Asn-Tyr-Tyr-Trp, Trp-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp,or in case of (2), Z representsTrp-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp-Z.sup.1Trp-Val-Tyr-Tyr-Ala-His-Leu-Asp-Ile-Ile-Trp-Z.sup.1Trp-Leu-Tyr-Phe-Ala-His-Gln-Asp-Val-Ile-Trp-Z.sup.1.

Abstract: The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.

Abstract: The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.

Abstract: The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. Also, a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.

Abstract: Compounds comprising a linear .beta.1.fwdarw.6 glucan esterified by caproic acid, the number of D-glucose residues being from 7 to 40 and the number of caproic acid residues being from 2 to 30, may be be obtained by fermentation of a microorganism of the genus Aureobasidium. These compounds are designated HS-142-1. Preferred microorganism is Aureobasidium pullulans var. melanigenum KAC-2383 (FERM-BP 2407).The compounds of the present invention exhibit excellent antagonistic activity to ANP and are capable of inhibiting the bonding of ANP to ANP receptors.

Abstract: A compound of formula (I): ##STR1## wherein R.sub.1 represents hydrogen, hydroxy or acetoxy and R.sub.2 represents hydroxy or acetoxy.The compounds are capable of protecting the nerve cells and also antagonistic activity against N-methyl-D-aspartic acid receptors.They may be prepared by fermentation of a microorganism of the genus Verticillium or a mutant thereof.

Abstract: A new substance K-259-2 having a molecular formula of C.sub.21 H.sub.18 O.sub.7, a molecular weight of 382 and an elemental analysis (%) of H: 4.50, C: 65.53 and N: 0. This substance is of interest in providing a new vasodilating agent in view of its ability to dilate the blood vessel, particularly the artery, of mammals. This substance may be obtained by fermentation of a microorganism Micromonospora sp. K-259 (FERM BP 569).

Abstract: A novel physiologically active substance K-252 having an antiallergic action is produced by culturing a microorganism of the genus Nocardiopsis.

Abstract: The antibacterial compound DC-38-V is produced by culturing a microorganism belonging to the genus Streptomyces.